Stocks · News reference
Filed: 2026-11-03 AccNo: 0000078003-26-000125 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pfizer (NYSE:PFE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Pfizer beats Q3 revenue and profit forecasts on oncology and non-COVID drug growth, raising its full-year 2026 sales and EPS outlook.
Pfizer reported strong Q3 results, beating analyst expectations with $16.6B in revenue (vs. $15.9B forecast) and $0.87 EPS (vs. $0.73 expected). The company raised full-year guidance and highlighted 32% growth from launched and acquired products. Trading at a modest 10x forward P/E with a 5.6% dividend yield, the stock may be positioned for further gains despite being down 30% over five years due to declining COVID-related revenues.
Pfizer Inc. announced its financial results for the third quarter of 2026 and increased its full-year 2026 revenue and adjusted diluted EPS guidance.
Pfizer Inc. has appointed Cecile Guegan as its permanent Chief Financial Officer and Executive Vice President, effective November 1, 2026.
Pfizer announced 18% year-over-year revenue growth for the second quarter, excluding currency effects, and increased its full-year revenue forecast midpoint by $500 million.